
Izberite svojo etiketo
prikazano neposredno na vialiLaboratorijsko poročilo
PDF- Testirano
- CagriSema (Cagri+Sema) 10mg (5+5)
- Laboratorij
- Analiza Białek
- Datum
- October 2026
- Rezultat
- 99% purity (Cagrilintide 5.29 mg + Semaglutide 5.15 mg)
- Endotoksini
- 5.73 EU/vial
- Št. naročila
- Geslo
Neodvisno testirano, preverljivo z geslom neposredno pri laboratoriju.
CagriSema (Cagri+Sema)
GLP-1
- Laboratorijsko testirano · Čistost 99 %
- Odprema iz Nemčije
Naročilo
- DHL s sledenjem
- Diskretna embalaža
Na prvi pogled
CagriSema (Cagri+Sema) v številkah
Ključni podatki iz našega leksikona.
Celoten vnos v leksikonu- Class
- Amylin analog + GLP-1 agonist
- Use
- Subcutaneousweekly
- Sizes
- 5 to 20 mg3 sizes in the shop
What studies show
All 2 sources in the lexicon- 20.4 %NEJM, 2025
- Unternehmensmitteilung des Herstellers, 20.12.2024
Znanje
Vse o CagriSema (Cagri+Sema)
Podrobne informacije bodo kmalu na voljo.
Odmerjanje
Nalaganje podatkov o odmerjanju …
Priporočljivo zraven
Kaj potrebujete zraven
Bakteriostatska voda se samodejno doda v vašo košarico. Brizge in robčki z enim klikom.
Inzulinske brizge
10 kos. · 5.50 €
Alkoholni robčki
50 kos. · 10 €
Koliko vode?
Enote na brizgi za vašo velikost viale.
Odpri kalkulator →Is CagriSema approved?
No, the combination is not approved (as of 26 October 2026). Semaglutide alone has been approved since 2017, ChEMBL lists cagrilintide with phase 3 as the highest phase. ClinicalTrials.gov lists 18 phase 3 trials of the combination, 10 of them completed.
What does the combination add over the single compounds?
In REDEFINE 1 the combination came out ahead after 68 weeks. For all participants: -20.4 percent versus -14.9 (semaglutide alone), -11.5 (cagrilintide alone) and -3.0 (placebo). When taken as planned: -22.7 versus -16.1, -11.8 and -2.3 percent. The values of the single compounds come from the manufacturer's announcement, the abstract only reports combination and placebo.
Why two compounds in one vial?
Because they act on different receptors. Cagrilintide binds to amylin and calcitonin receptors, semaglutide to the GLP-1 receptor. In rats cagrilintide worked through specific nerve cells in the brainstem that semaglutide did not need. The effects on satiety and the stomach thus add up.
What do the trials show in type 2 diabetes?
In REDEFINE 2 weight fell by 13.7 percent after 68 weeks (placebo 3.4), 73.5 percent reached an HbA1c of 6.5 percent or below (placebo 15.9). In phase 2 HbA1c fell by 2.2 percentage points in 32 weeks. In REIMAGINE 2 the combination was slightly but significantly ahead of semaglutide alone on HbA1c.
How long do the compounds stay in the body?
In the first study of the combination the half-life of cagrilintide was 159 to 195 hours, that of semaglutide 145 to 165 hours, so both about one week. Cagrilintide did not change semaglutide blood levels. That is why the trials give the combination once a week.
Which side effects were seen?
Mainly gastrointestinal effects such as nausea, vomiting, diarrhoea or constipation: in REDEFINE 1 in 79.6 percent (placebo 39.9), in REDEFINE 2 in 72.5 percent (placebo 34.4). According to the trials they were mostly mild to moderate and passed.
How did the combination do directly against semaglutide?
In REDEFINE 5 in Japan and Taiwan weight fell by 18.4 percent with the combination after 68 weeks, by 11.9 percent with semaglutide alone. Gastrointestinal effects were similarly common in both groups (53 versus 51 percent).
Sorodno
Sorodni izdelki
Tirzepatide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
10 velikosti
Laboratorijsko testirano
= od 10 €/vialo
Retatrutide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
11 velikosti
Laboratorijsko testirano
= od 16 €/vialo
Semaglutide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
6 velikosti
Laboratorijsko testirano
= od 10 €/vialo
Mazdutide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
2 velikosti
= od 32 €/vialo
CagriSema (Cagri+Sema)